RBC Capital Keeps Their Buy Rating on Infinity Natural Resources, Inc. Class A (INR)
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
According to TipRanks, Hanold is a top 25 analyst with an average return of 30.6% and a 70.22% success rate. Hanold covers the Energy sector, focusing on stocks such as EOG Resources, Matador Resources, and Expand Energy.
Infinity Natural Resources, Inc. Class A has an analyst consensus of Strong Buy, with a price target consensus of $25.75, implying a 54.75% upside from current levels. In a report released on June 30, Citi also maintained a Buy rating on the stock with a $25.00 price target.
The company has a one-year high of $23.00 and a one-year low of $13.64. Currently, Infinity Natural Resources, Inc. Class A has an average volume of 286.9K.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Merck & Co. (MRK) Announces that US FDA Approves ENFLONSIA™ For Preventing RSV Lower Respiratory Tract Disease
Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants who were born during or entering their first RSV season. To provide a brief context, ENFLONSIA happens to be a preventive, long-acting monoclonal antibody (mAb) which has been designed to offer direct, rapid, and durable protection through 5 months, a typical RSV season, with the same 105 mg dose irrespective of weight. Merck & Co., Inc. (NYSE:MRK) further mentioned that the typical RSV season generally spans autumn to spring of the next year. A close-up of a person's hand holding a bottle of pharmaceuticals. However, ENFLONSIA should not be administered to infants who have a history of serious hypersensitivity reactions, including anaphylaxis, to any of the components of ENFLONSIA. Merck & Co., Inc. (NYSE:MRK) added that the approval is basis the results from the pivotal Phase 2b/3 CLEVER trial (MK-1654-004) evaluating a single dose of ENFLONSIA administered to preterm and full-term infants. Furthermore, the focus is to ensure the availability of ENFLONSIA in the US before the upcoming RSV season begins. This is to help in reducing the significant burden of the widespread seasonal infection on families and health care systems. Artisan Partners, an investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'Shares of Merck & Co., Inc. (NYSE:MRK), a health care solutions company, were down 9%. Operating results have been solid, with Q4 earnings beating expectations, but investors were more focused on the continued weak demand in China for Gardasil, a vaccine for human papillomavirus (HPV), and the company's decision to pause vaccine shipments through at least mid-2025 to pare inventories. Though recent Gardasil setbacks have weighed on sentiment, the overarching issue for shareholders remains the success of Merck's late-stage pipeline to replace sales that will be lost when blockbuster oncology drug Keytruda (50% of Q4sales) comes off patent in 2028. As shares sell cheaply at just 10X earnings, Merck seems to be getting little credit from investors for the 60+ programs it has in clinical development, despite having several solid and large new product opportunities. Additionally, the company's strong balance sheet and robust free cash flow provide it multiple options for future partnerships and acquisitions, besides return of capital to shareholders via dividends and share repurchases.' While we acknowledge the potential of MRK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRK and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds' investor letters by entering your email address below. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Trump says there likely won't be a trade deal with ‘spoiled' Japan
President Trump says Japan, which he characterized as 'spoiled,' will likely not make a deal with the United States on a tariff rate ahead of the looming deadline next week. 'We dealt with Japan. I'm not sure if we're going to make a deal. I doubt it with Japan — they're very tough. You have to understand, they're spoiled. I love Japan. I really like the new prime minister, too. Abe was one of my closest friends, as you know,' he said on Tuesday, referring to former Japanese prime minister Shinzo Abe who died in 2022. The president hosted the current Japanese prime minister, Shigeru Ishiba, at the White House in February. Trump noted this week that Japan has a rice crisis that has elevated prices, arguing the country should turn to the U.S. for rice. 'But they and others are so spoiled from having ripped us off for 30, 40 years that it's really hard for them to make a deal. You know, it's very hard. As an example with Japan, they won't take rice, and yet they desperately need rice,' he said. 'They won't take any cars, but they'll sell millions. So, we told them, 'Sorry you can't do that.'' The president said Japan will likely get a letter that would set the tariff rate ahead of the July 8 expiration of the 90-day pause on country-specific tariffs. Trump has said he will send letters soon to trading partners who haven't struck deals. 'So what I'm going to do is I'll write them a letter, say, 'We thank you very much. We know you can't do the kind of things that we need, and therefore you'll pay a 30 percent, 35 percent or whatever the numbers that we determine,'' he said. 'Because we also have a very big trade deficit with Japan, as you know and it's very unfair to the American people.' Trump on Monday also suggested Japan would not get a trade deal with the U.S., sharing on Truth Social, 'To show people how spoiled Countries have become with respect to the United States of America, and I have great respect for Japan, they won't take our RICE, and yet they have a massive rice shortage.' Officials, though, have insisted for months that talks are progressing with trading partners, including with Japan, as well as with India and Vietnam. The administration has been working on trade deals during the 90-day tariff pause, but only agreements with China and the United Kingdom have been announced, despite the self-imposed ambitious goal of 90 deals in 90 days. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Private-sector payrolls lose 33,000 jobs, surprising analysts
Private-sector employers cut 33,000 jobs in June, the first monthly decline in more than two years, according to the ADP National Employment Report released Wednesday. The latest report comes as a surprise to economists who had anticipated a gain of about 100,000 jobs last month. Service-providing industries led the losses with a net decline of 66,000 jobs in June, including a loss of 56,000 professional and business services jobs and 52,000 in the education and health services industries. Companies in the service industries, meanwhile, saw gains of 32,000 jobs in leisure and hospitality and of 14,000 added in trade, transportation and utilities. Goods-producing firms, meanwhile, saw a net gain of 32,000 jobs, including in natural resources and mining, construction and manufacturing. Broken down by region, the South saw 13,000 jobs added, while the Midwest lost 24,000 jobs, the West lost 20,000 jobs, and the Northeast lost 3,000 jobs. Small establishments — with fewer than 50 employees — lost 47,000 jobs. Meanwhile, large establishments — with 500 or more employees — saw gains of 30,000 jobs. Medium-size establishments were split: Businesses with 50 to 249 employees gained 12,000 jobs last month, while businesses with 250 to 499 employees lost 27,000 positions. The latest ADP report shows annual pay up 4.4 percent year over year in June for people who stayed in their jobs — little changed from the 4.5 percent in May. For those who switched jobs, however, annual pay in June increased 6.8 percent year over year, a slight drop from the 7 percent in May. 'Though layoffs continue to be rare, a hesitancy to hire and a reluctance to replace departing workers led to job losses last month,' ADP chief economist Nela Richardson said in a statement. 'Still, the slowdown in hiring has yet to disrupt pay growth.' The latest report also revised downward the total number of jobs added in May from 37,000 to 29,000. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
